Small Pharma to Host Virtual Roundtable Event with Key Opinion Leaders in Psychiatry Post published:March 7, 2023 Post category:Press Release
Small Pharma Announces Further Positive Data from SPL026 Phase IIa Trial in Major Depressive Disorder Strengthening Topline Efficacy Results Post published:March 7, 2023 Post category:Press Release
Small Pharma to Present at Cowen’s 43rd Annual Health Care Conference Post published:March 1, 2023 Post category:Press Release
First Subject Dosed in Small Pharma’s First-in-Human Phase I Clinical Trial with SPL028 Post published:February 15, 2023 Post category:Press Release
Small Pharma Announces Update on Intellectual Property Portfolio with Two New Patents Approved for Issue Post published:February 1, 2023 Post category:Press Release
Small Pharma Reports Fiscal Third Quarter 2023 Highlights Post published:January 25, 2023 Post category:Press Release
Small Pharma Reports Positive Top-line Results from Phase IIa Trial of SPL026 in Major Depressive Disorder Post published:January 25, 2023 Post category:Press Release
Small Pharma To Announce Results of SPL026 Phase IIa Trial for Major Depressive Disorder and Host Conference Call on Wednesday, January 25 Post published:January 24, 2023 Post category:Press Release
First Patient Dosed in Small Pharma’s Phase I Study Exploring Intramuscular Administration of SPL026 Post published:January 15, 2023 Post category:Press Release
Small Pharma Announces Completion of SPL026 Phase IIa Trial and Secures New Intellectual Property Post published:December 24, 2022 Post category:Press Release